Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior.

Full top-line data from this trial were presented yesterday for the first time as an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives, in Salzburg, Austria, by the study's lead investigator, Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston.

New data presented in Salzburg included the magnitude and levels of statistical significance by which the Dimebon-treated patients outperformed the placebo-treated patients on the Mini Mental State Exam (MMSE: p<0.0001), the Alzheimer's Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL: p=0.002), and the Neuropsychiatric Inventory (NPI: p=0.006). As previously reported, Dimebon-treated patients also demonstrated significant improvement versus placebo on both the primary and key secondary endpoints in this study -- the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog: p<0.0001) and the Clinician's Interview-Based Impression of Change with a caregiver interview (CIBIC-plus: p<0.0001). Dimebon was well tolerated in this study.

"In my experience, the results of this study are particularly striking for two primary reasons," said Dr. Doody. "First, Dimebon produced statistically significant improvement over pl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/24/2009)...Accumetrics,Inc.,aprivately-helddeveloperandmarket...to-usediagnosticsystemformeasuringanindividual,sre...;andaspirin),announcedtodaythatTimothyI.Still,Pres...fFinancialOfficerofAccumetrics,willbepresentingaco...reConferencebeingheldinNewYorkCityonDecember1-2,20...
(Date:11/24/2009)...e/-- InfiniteMind ,aSaltLakeCitybasedsoftwarecompa...rameyeQ,thesoftwareprogramistobeusedinconjunctionw...sintroducedattheCOVDconferencethisOctoberinColorad...lievesthe eyeQ programaddssignificantvaluetohispra...shispatientstoembedpracticesfromtheofficesettingto...
(Date:11/24/2009)...-Asia/--HuifengBio-Pharmaceutical,Technology,Inc.(...r,ofplantextractsandpharmaceuticalrawmaterialsforu...inXi,an,China,todayreportedthatinits,thirdquarter,...evenuesforthequarterendedSept.30,2009were$4,465,77...samequarterin2008.Netincome,amountedto1,002,005,or...
Breaking Medicine Technology:Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Sundia Receives the Highest Growth Potential Award from Zhangjiang 55681 1Sundia Receives the Highest Growth Potential Award from Zhangjiang 55681 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 1BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 3Sanofi Aventis 3A Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4919 1Sanofi Aventis 3A Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4919 2Sanofi Aventis 3A Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4919 3Sanofi Aventis 3A Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4919 4
...(Nasdaq: TRBN ), today announced that Wyeth Pharm...al of TRU-015, Trubion,s lead Small,Modular Immuno...treatment,of non-Hodgkin,s lymphoma (NHL). The non...assignment clinical trial is designed to,evaluate ...h NHL. Trubion,is co-developing TRU-015 and other ...
...ure babies, FORT WORTH, Texas, Dec. 10 Bubbles h...e helping improve the care of,premature infants. H...tal,intensive care unit recently implemented the u...stem showing promising results in decreasing the,i...nfants. One of two,hospitals in the Metroplex curr...
Other Medicine Technology:Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma 2Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma 3Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin's Lymphoma 4Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe 2
(Date:11/25/2009)...o signaling pathways essential to normal human dev...owth factor receptor (EGFR) pathways - interact in...astasis, researchers from The University of Texas ... issue of Molecular Cell . , This newly charact...ents known to correlate with invasive cancer - act...
(Date:11/25/2009)...ov. 25, 2009) Melvin R. Kaplan, MD, FACP, a forme...rch institute that became Los Angeles Biomedical R...A BioMed), will be honored by the American College...re of patients. , At its April 22, 2010 meeting ...l present Dr. Kaplan with the Ralph O. Claypoole S...
(Date:11/25/2009)...5, 2009 Physicians at UT Southwestern Medical Cen...ed to improve breathing in patients with upper spi... from breathing independently. , UT Southwester...y two sites in Texas and one of 25 in the country ...he NeuRx Diaphragm Pacing System. , The device i...
(Date:11/25/2009)...tify role mitochondrial function plays in insulin ...hDay News) -- Mitochondrial damage causes people w...s, a finding that could lead to new treatments, U....gy for cellular activity. , The researchers fou...ancreas can,t respond to circulating insulin, it t...
(Date:11/25/2009)... PCU College teaches students to use natu... , Burnaby, BC (Vocus) No... radiation are the standard, effective treatments ...o alternative medicine to help them cope with the ...creased number of cancer patients using acupunctur...
Breaking Medicine News(10 mins):Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:1 of LA BioMed's founders to be honored 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2Health News:Holistic and Western Medicine Combined Can Fight Cancer 2
... Kreager, Director of,Clinical Quality and Standar... Group, Inc. (LTCG), has been elected President of...he Long Term Care International Forum,( http://www...e industry., (Logo: http://www.newscom.com/cgi-b...
...lobal Health,innovator IntraHealth International w...ew five-year contract to improve public health nee...project was awarded to Washington,DC-based Chemoni...Project aims to improve the,health status of Pales...
...chers at UT Southwestern Medical Center have uncov...e" nature of a protein that stimulates stem-cell m...o lead to nerve-cell damage. , In two separate s... research teams studied the protein Cdk5 and disco...
...onal Primate Research Center, Emory University, ha... growth and generation of several types of neural ...October issue of the journal Stem Cells , suggest...tem. , Dental stem cells are adult stem cells, on...
...ice partners with AMICAS for growth and ...AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiolog...utions, today announced a new partnership with Ark...uctivity and,achieve this practice,s growth initia...
...1 To support,manufacturers developing affordable,...) (NYSE: TXN ) today introduced a family of fully... TX734, the first device in the TX7xx,family, is a...duces board space by 50 percent compared to discre...
Other Medicine News:Health News:Long Term Care International Forum names LTCG's Pam Kreager as President 2Health News:IntraHealth to Support Health Reform in Palestine 2Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 2Health News:Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find 3Health News:Radiology Associates, P.A. Chooses AMICAS 2Health News:Radiology Associates, P.A. Chooses AMICAS 3Health News:Video: Ultrasound Systems Can Produce Clearer Images With TI's New Family of Fully Integrated High-Voltage Pulsers and Switches 2Health News:Video: Ultrasound Systems Can Produce Clearer Images With TI's New Family of Fully Integrated High-Voltage Pulsers and Switches 3Health News:Video: Ultrasound Systems Can Produce Clearer Images With TI's New Family of Fully Integrated High-Voltage Pulsers and Switches 4
...de; Collar is completely injected molded from high...es our patented chin support. , ,Our one-piece de...anaged where space is limited. Color-coded labels ...zes., ,Either in a supine or seated position, app...
...nd cold therapy Gel Pad. Our Gel Pad helps defeat ... swelling and /or hot therapy to increase blood fl...d therapy gel pad, place an "E" before the item nu...rt upon request. Please specify sewn-in or removab...
...rior immobilization and cervical spine care, one p...the most important function of a cervical collar i...not know is that independent studies prove that Je...bilization over the leading one-piece rigid collar...
MODEL C-10 Becker Swivel Cervical Orthosis
Medicine Products: